PMN

ProMIS Neurosciences Inc

Feb 26 • 04:00PM ET

20.86

+1.00 5.04 %

Healthcare • Biotechnology • Canada • NASD

Peers: LLY BIIB REGN VRTX SAVA IONS ACAD AVXL NBIX PRTA

Index	-	P/E	-	EPS (ttm)	-18.64	Insider Own	16.67%	Shs Outstand	2.15M	Perf Week	29.08%
Market Cap	44.90M	Forward P/E	-	EPS next Y	-6.31	Insider Trans	204.21%	Shs Float	1.79M	Perf Month	95.68%
Enterprise Value	29.47M	PEG	-	EPS next Q	-4.66	Inst Own	48.09%	Short Float	7.14%	Perf Quarter	155.87%
Income	-29.28M	P/S	-	EPS this Y	-757.82%	Inst Trans	-15.18%	Short Ratio	0.76	Perf Half Y	51.99%
Sales	0.00M	P/B	4.89	EPS next Y	65.13%	ROA	-127.41%	Short Interest	0.13M	Perf YTD	205.64%
Book/sh	4.27	P/C	2.91	EPS next 5Y	-	ROE	-355.80%	52W High	39.75 -47.52%	Perf Year	8.36%
Cash/sh	7.17	P/FCF	-	EPS past 3/5Y	- -	ROIC	-318.73%	52W Low	6.27 232.70%	Perf 3Y	-83.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.38% 13.16%	Perf 5Y	-86.33%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-273.84%	Oper. Margin	-	ATR (14)	1.63	Perf 10Y	-66.08%
Dividend Ex-Date	-	Quick Ratio	1.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	82.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.76	EPS Q/Q	-176.86%	SMA20	35.04%	Beta	-0.16	Target Price	34.38
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	85.75%	Rel Volume	0.28	Prev Close	19.86
Employees	7	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	73.84%	Avg Volume	167.24K	Price	20.86
IPO	Jan 16, 2007	Option/Short	No / Yes	EPS/Sales Surpr.	17.24% -	Trades		Volume	46,185	Change	5.04%

Feb-09-26 08:35AM	Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack (24/7 Wall St.)
Feb-04-26 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -16.29%
Jan-30-26 08:00AM	ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing (GlobeNewswire) +17.95%
Dec-18-25 07:30AM	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease (GlobeNewswire) -5.61%
Dec-10-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk (GlobeNewswire) +12.00%
07:30AM	Loading…
Dec-01-25 07:30AM	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 (GlobeNewswire)
07:00AM	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-24-25 08:00AM	ProMIS Neurosciences Announces Reverse Stock Split (GlobeNewswire) -22.36%
Nov-12-25 07:00AM	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
Nov-03-25 04:05PM	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-22-25 07:30AM	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-03-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -14.76%
07:00AM	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 (GlobeNewswire)
Aug-13-25 07:00AM	ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
08:00AM	Loading…
Jul-29-25 08:00AM	ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference (GlobeNewswire) -6.67%
Jul-28-25 07:00AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -8.76%
Jul-22-25 07:01AM	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire) -26.79%
07:00AM	ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +154.49%
08:00AM	ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease (GlobeNewswire)
Jun-17-25 07:00AM	ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
May-12-25 07:30AM	ProMIS Neurosciences Announces First Quarter 2025 Financial Results (GlobeNewswire)
Mar-31-25 07:00AM	ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-24-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference (GlobeNewswire)
Mar-13-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-11-25 07:30AM	ProMIS Neurosciences to Participate in the 37th Annual Roth Conference (GlobeNewswire)
Feb-25-25 07:00AM	ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease (GlobeNewswire) -6.19%
Jan-29-25 07:30AM	ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 10:30AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire)
07:00AM	Loading…
Jan-10-25 07:00AM	ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease (GlobeNewswire)
Nov-26-24 07:00AM	ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-14-24 09:15AM	ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-12-24 07:00AM	ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-30-24 08:00AM	ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire) +5.83%
Oct-13-24 02:58PM	ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now (Insider Monkey)
Sep-12-24 07:00AM	ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences (GlobeNewswire)
Sep-05-24 07:00AM	ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-08-24 07:00AM	ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -11.51%
Aug-06-24 07:00AM	ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology (GlobeNewswire) +18.33%
Aug-01-24 07:00AM	ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-30-24 08:30AM	ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -17.43%
Jul-26-24 08:35AM	ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial (GlobeNewswire) -20.70%
08:30AM	ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing (GlobeNewswire)
May-15-24 09:54AM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 (InvestorPlace) -7.22%
May-14-24 04:01PM	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Apr-30-24 07:00AM	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies (GlobeNewswire)
Apr-09-24 07:00AM	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS (GlobeNewswire)
Apr-04-24 07:00AM	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April (GlobeNewswire)
Apr-01-24 10:53PM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 (InvestorPlace) +7.33% +10.15%
04:15PM	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-11-24 07:00AM	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio (GlobeNewswire)
Feb-22-24 07:00AM	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -10.14%
Jan-22-24 07:00AM	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) +7.24%
Jan-08-24 07:00AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire) +5.45%
Jan-03-24 07:00AM	ProMIS Neurosciences, Inc. Announces Leadership Transition (GlobeNewswire) -7.82%
Dec-20-23 07:00AM	ProMIS Neurosciences Announces Publication on Novel Target for ALS (GlobeNewswire)
Nov-20-23 07:00AM	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease (GlobeNewswire) +6.67%
Nov-14-23 04:30PM	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -12.22% +9.36%
Sep-08-23 07:00AM	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing (GlobeNewswire)
Sep-06-23 12:18PM	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:12PM	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing (GlobeNewswire) -9.14% +20.75%
Aug-14-23 05:33PM	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.33%
Jul-17-23 07:00AM	ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline (GlobeNewswire) +120.28%
Jul-14-23 07:45AM	ProMIS Announces Completion of Continuance (GlobeNewswire)
Jul-10-23 07:55AM	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange (GlobeNewswire) -8.11%
Jun-30-23 08:00AM	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved (GlobeNewswire)
Jun-29-23 08:00AM	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time (GlobeNewswire)
May-15-23 05:00PM	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.16%
May-08-23 09:00AM	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease (GlobeNewswire)
Apr-25-23 05:00PM	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease (GlobeNewswire)
Apr-24-23 07:30AM	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.31%
Apr-10-23 07:30AM	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 (GlobeNewswire)
Mar-29-23 08:30AM	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023 (GlobeNewswire)

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaplan Johanne	Chief Development Officer	Feb 19 '26	Buy	15.35	1,629	25,005	3,941	Feb 23 08:31 AM
ABG Management Ltd.	10% Owner	Feb 03 '26	Buy	12.13	700,741	8,499,988	943,090	Feb 05 07:00 PM
Milbury Max A.	Principal Accounting Officer	Oct 03 '25	Buy	0.49	30,392	14,929	45,389	Oct 06 09:12 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMN

ProMIS Neurosciences Inc

Upgrade your FINVIZ experience